biotechnology

Matt's Take Matthew Herper

STAT Plus: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone

Politics Rachel Cohrs

STAT Plus: Pharma giants, government spar in court over Medicare drug price negotiation

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: VC turmoil, GLP-1 competition, & the war on recovery

The Readout Damian Garde

STAT Plus: Banning WuXi is more complicated than it might sound

Biotech Allison DeAngelis

STAT Plus: Novo Nordisk’s obesity pill bests Wegovy in early trial

Biotech Adam Feuerstein

STAT Plus: A deep dive into Applied Therapeutics’ data, and questions on Cassava’s erased data

Politics Rachel Cohrs

STAT Plus: Biden to propose expanding Medicare drug price negotiation in State of the Union

Politics John Wilkerson

STAT Plus: Senate panel advances bill to ban some Chinese biotechs, with Sen. Paul taking up industry’s cause

The Readout Damian Garde

STAT Plus: Bayer’s not breaking up. At least not yet

Biotech Allison DeAngelis

STAT Plus: Startup Alumis raises $259 million as it prepares for psoriasis trial

The Readout Damian Garde

STAT Plus: Where’s Lilly’s Alzheimer’s approval?

The Readout Meghana Keshavan

STAT Plus: Serum Institute of India wants government HPV contract

Biotech Adam Feuerstein

STAT Plus: Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout Meghana Keshavan

STAT Plus: Despite good data, Ironwood’s shares plummet 

Exclusive Allison DeAngelis

STAT Plus: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships

Politics John Wilkerson

STAT Plus: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector?

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: Legal insider trading, booming biotech stocks, & the next GLP-1

The Readout Damian Garde

STAT Plus: The next act for a biotech rainmaker

Biotech Matthew Herper

STAT Plus: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

Exclusive Allison DeAngelis

STAT Plus: Biotech launches with $82 million for Parkinson’s cell therapy

Biotech Allison DeAngelis

STAT Plus: Q&A: A biotech VC leader shares her next big bets

Pharma Matthew Herper

STAT Plus: Pfizer is about to make a big push in cancer. Will investors listen?

Adam's Take Adam Feuerstein

STAT Plus: An inside look at PIPEs, the financing trend that has biotech abuzz

Exclusive Ed Silverman

STAT Plus: White House to hold a listening session on reforming pharmacy benefit managers

The Readout Damian Garde

STAT Plus: Beam is trading like it’s 2021

Biotech Damian Garde

STAT Plus: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

The Readout Meghana Keshavan

STAT Plus: GSK pill works in uncomplicated gonorrhea

The Readout Damian Garde

STAT Plus: The FDA isn’t afraid to yank a disappointing drug